Skip to main content
Market icon
Teknolohiya·Drug

Inaprubahan ng FDA ang Retatrutide ngayong taon?

Market icon
Teknolohiya·Drug

Inaprubahan ng FDA ang Retatrutide ngayong taon?

18% tsansa
Polymarket

$560,784 Vol.

18% tsansa
Polymarket

$560,784 Vol.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Trader consensus on an 81.5% implied probability for "No" FDA approval of retatrutide in 2026 stems from the absence of a New Drug Application (NDA) filing by Eli Lilly, with Phase 3 trials in the TRIUMPH obesity program and TRANSCEND type 2 diabetes program still ongoing—some with estimated completion dates into May 2026 per ClinicalTrials.gov. Positive topline data from TRANSCEND-T2D-1 on March 19 showed retatrutide achieving superior A1C reductions of 1.7–2.0% and up to 16.8% mean weight loss at 40 weeks versus placebo, building on TRIUMPH-4's 28.7% weight loss reported in December 2025, yet full datasets from seven additional trials are needed before submission. Standard FDA review requires 10 months, or 6 months with priority review, rendering 2026 approval improbable without an imminent filing and fast-track designation; upcoming readouts later this year will clarify timelines.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$560,784
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
Jan 12, 2026, 5:52 PM ET

Resolver

0x65070BE91...
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Trader consensus on an 81.5% implied probability for "No" FDA approval of retatrutide in 2026 stems from the absence of a New Drug Application (NDA) filing by Eli Lilly, with Phase 3 trials in the TRIUMPH obesity program and TRANSCEND type 2 diabetes program still ongoing—some with estimated completion dates into May 2026 per ClinicalTrials.gov. Positive topline data from TRANSCEND-T2D-1 on March 19 showed retatrutide achieving superior A1C reductions of 1.7–2.0% and up to 16.8% mean weight loss at 40 weeks versus placebo, building on TRIUMPH-4's 28.7% weight loss reported in December 2025, yet full datasets from seven additional trials are needed before submission. Standard FDA review requires 10 months, or 6 months with priority review, rendering 2026 approval improbable without an imminent filing and fast-track designation; upcoming readouts later this year will clarify timelines.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$560,784
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
Jan 12, 2026, 5:52 PM ET

Resolver

0x65070BE91...
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Mag-ingat sa mga external link.

Mga Madalas na Tanong

Ang "Inaprubahan ng FDA ang Retatrutide ngayong taon?" ay isang prediction market sa Polymarket kung saan bumibili at nagbebenta ang mga trader ng "Yes" o "No" shares batay sa kung naniniwala silang mangyayari ang event na ito. Ang kasalukuyang crowd-sourced probability ay 18% para sa "Yes." Halimbawa, kung ang "Yes" ay naka-presyo sa 18¢, ang market ay kolektibong nagtatakda ng 18% na tsansa na mangyayari ang event na ito. Patuloy na nagbabago ang mga odds na ito habang tumutugon ang mga trader sa mga bagong development at impormasyon. Ang mga shares sa tamang outcome ay mare-redeem sa $1 bawat isa sa market resolution.

Sa ngayon, ang "Inaprubahan ng FDA ang Retatrutide ngayong taon?" ay naka-generate ng $560.8K sa kabuuang trading volume mula nang ilunsad ang market noong Jan 12, 2026. Ang antas na ito ng trading activity ay sumasalamin sa malakas na engagement mula sa Polymarket community at tumutulong na matiyak na ang kasalukuyang odds ay sinusuportahan ng malawak na pool ng mga market participant. Maaari mong subaybayan ang live price movements at mag-trade sa anumang outcome nang direkta sa pahinang ito.

Para mag-trade sa "Inaprubahan ng FDA ang Retatrutide ngayong taon?," piliin lang kung naniniwala ka na ang sagot ay "Yes" o "No." Ang bawat panig ay may kasalukuyang presyo na sumasalamin sa implied probability ng market. Ilagay ang iyong halaga at i-click ang "Trade." Kung bibili ka ng "Yes" shares at na-resolve ang outcome bilang "Yes," nagbabayad ang bawat share ng $1. Kung na-resolve bilang "No," ang iyong "Yes" shares ay nagkakahalaga ng $0. Maaari ka ring magbenta ng iyong shares anumang oras bago ang resolution kung gusto mong i-lock in ang kita o bawasan ang pagkalugi.

Ang kasalukuyang probability para sa "Inaprubahan ng FDA ang Retatrutide ngayong taon?" ay 18% para sa "Yes." Ibig sabihin nito na kasalukuyang naniniwala ang Polymarket crowd na may 18% tsansa na mangyayari ang event na ito. Nag-a-update ang mga odds na ito sa real-time batay sa actual trades, na nagbibigay ng patuloy na ina-update na signal kung ano ang inaasahan ng market na mangyayari.

Ang mga resolution rules para sa "Inaprubahan ng FDA ang Retatrutide ngayong taon?" ay tiyak na nagde-define kung ano ang kailangang mangyari para sa bawat outcome na maideklara bilang panalo — kasama ang mga opisyal na data source na ginagamit para matukoy ang resulta. Maaari mong i-review ang kumpletong resolution criteria sa "Rules" section sa pahinang ito sa itaas ng mga komento. Inirerekomenda namin na basahin nang mabuti ang mga patakaran bago mag-trade, dahil tinutukoy nila ang mga tiyak na kondisyon, edge cases, at mga source na namamahala kung paano nise-settle ang market na ito.